Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	1.25T +107.0%
Revenue (ttm)	1.27T +21.4%
Net Income	-109.88B
EPS	-1,637.00
Shares Out	92.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	466,332
Average Volume	429,113
Open	14,050
Previous Close	13,930
Day's Range	12,700 - 14,050
52-Week Range	9,690 - 23,950
Beta	n/a
RSI	25.40
Earnings Date	May 21, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2025, Chabiotech's revenue was 1.27 trillion, an increase of 21.36% compared to the previous year's 1.05 trillion. Losses were -109.88 billion, 2206.6% more than in 2024.